Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation. Issue 5 (May 2015)

• Record Type: Journal Article
• Authors: Gifford, G.; Fay, K.; Jabbour, A.; Ma, D. D.
• Is Part Of: Internal medicine journal. Volume 45:Issue 5(2015)
• Page Start: 583
• Page End: 586
• Publication Date: 2015-05
• Subjects: Medicine -- Periodicals; 616
• DOI: 10.1111/imj.12735
• Languages: English
• ISSNs: 1444-0903

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <p>Primary central nervous system posttransplantation lymphoproliferative disorder (PCNS‐PTLD) is uncommon, especially after heart or lung transplantation. Database analysis from a single heart and lung transplantation centre and a literature review pertaining to PCNS‐PTLD was performed. In this study, the prevalence of PCNS‐PTLD was 0.18% after heart and/or lung transplants. Of 1674 transplants, three cases of PCNS‐PTLD developed 14 months, 9 years and 17 years posttransplant, and all were Epstein–Barr virus driven malignancies. Literature review of the topic revealed predominantly retrospective studies, with most reported cases after renal transplantation. The overall survival is poor, and it may be improved by early diagnosis and treatment. There are no published guidelines on the management of PCNS‐PTLD; immune‐chemotherapy in conjunction with reduction of immune suppression is preferred based on available evidence.</p> </abstract>